Trial Condition(s):

Coronary artery disease

Vericiguat drug-drug interaction with nitroglycerin in stable coronary artery disease patients (VENICE)

Bayer Identifier:

17849

ClinicalTrials.gov Identifier:

NCT02617550

EudraCT Number:

2015-001444-11

Study Completed

Trial Purpose

This study is intended to investigate the effect of nitroglycerin on vericiguat in patients with stable coronary artery disease (CAD). Nitroglycerin is the standard therapy to treat acute crisis of angina. Thus there is a high likelihood of co-administration of both drugs in the target indication of vericiguat, worsening heart failure (HF). Therefore, it is important to investigate the safety and tolerability of vericiguat and nitroglycerin, which may be used as unprescribed on-demand treatment by patients with acute episodes of angina pectoris.

Inclusion Criteria
Patients with stable CAD defined by 
 -  coronary artery stenosis in any of the 3 main coronary vessels > 50% documented by coronary angiography within last 36 months or history of myocardial infarction 
 -  Age: 30 to 80 years 
 -  Body mass index (BMI): above/equal 18.0 and below/equal 36.0 kg / m²
 -  Female subjects must be of non-childbearing potential
Exclusion Criteria
-  Intervention e.g. revascularization by percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) during the last 3 months
 -  Progressive angina with symptoms of worsening of angina within the < 3 months 
 -  History of recent (< 6 months prior to the first screening examination) myocardial infarction or unstable angina
 -  Symptomatic carotid stenosis, or transient ischemic attack or stroke within 3 months prior or patients with stroke at more than 3 months prior with significant residual neurologic involvement
 -  Insulin dependent diabetes mellitus
 -  Clinically relevant cardiac ischemia
 -  Clinical significant persistent ischemia
 -  Atrial fibrillation, pacemaker, defibrillator, atrial ventricular (AV)-block II and III 
 -  Systolic blood pressure below 110 or above 160 mmHg
 -  Diastolic blood pressure above 100 mmHg 
 -  Heart rate below 50 or above 100 beats / min
 -  Estimated glomerular filtration rate < 30 mL/min/1.73m2

Trial Summary

Enrollment Goal
36
Trial Dates
black-arrow
Phase
1
Could I receive a placebo?
Yes
Products
Verquvo (Vericiguat, BAY1021189)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Bonn, Germany, 53105

Status
Completed
 
Locations

Investigative Site

Wuppertal, Germany, 42283

Status
Completed
 
Locations

Investigative Site

Hamburg, Germany, 20251

Status
Completed
 
Locations

Investigative Site

Heidelberg, Germany, 69120

Status
Completed
 
Locations

Investigative Site

Berlin, Germany, 13353

Status
Completed
 
Locations

Investigative Site

Erfurt, Germany, 99084

Status
Completed
 

Trial Design